Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab for Prevention of Bone Complications After Allogenic HSCT in Children
NCT02677246Phase 1Withdrawn
- Sponsor
- Centre Hospitalier Universitaire Sainte-Justine
- Start
- Dec 2016
- Primary completion
- Sep 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of denosumab, sponsored by Centre Hospitalier Universitaire Sainte-Justine. Primary endpoint: Maximum Tolerable Dose at 6 months. Planned start Dec 2016; status: withdrawn.
02
Drugs
denosumab
Beyond the preview
Go deeper on NCT02677246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02677246.